News

The aim of the collaboration is to develop a new class of medication with a novel mechanism of action for the treatment of pain and inflammatory diseases. The

The study was designed to evaluate the safety and immunomodulatory effects of SCV-07 as a monotherapy and in combination with ribavirin in relapsed HCV patients. The study results

CEL-SCI claims that Multikine is its immunotherapy developed as a first-line standard of care in treating head and neck cancer. The Phase III trial will be run at

Under the terms of the agreement, EMD Serono will be responsible for promotion, distribution, and patient support services and Ipsen will retain ownership of the product. The agreement

In European studies, Esmya has been shown to be an effective and safe treatment for uterine fibroids (myoma). The product is currently in late stage development in Europe

A-CUBE is a venture capital-backed company funded by JAIC and yet2.com, which uses proprietary in silico algorithms to predict and monetize novel drug targets related to blockbuster drugs.

Through the partnership, the NextGen integrated technology platform will connect the Wills Eye community, giving care providers access to electronic health records and enabling exchange of patient data

In Australia, Aspen and Sigma‘s Pharmaceutical Division compete in a number of pharmaceutical markets, including in the supply of various prescription generic medicines and over-the-counter pharmaceutical products. In

Generex claims that the new Canadian Patent no. 2,354,148 titled Aerosol Formulations for Buccal and Pulmonary Application increases the number of issued patents related to the its buccal